Search results
Your search for process/pmg6 returned no results
Showing 331 to 345 of 2854 results for process
Showing 331 to 345 of 2854 results for process
Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal) (TA625)
NICE is unable to make a recommendation on recombinant human parathyroid hormone for treating hypoparathyroidism. This is because Shire Pharmaceuticals (now part of Takeda) did not provide an evidence submission.
Show all sections
Sections for TA625
NICE is unable to make a recommendation on ramucirumab (Cyramza) for treating unresectable hepatocellular carcinoma in adults who have had sorafenib. This is because Lilly did not provide an evidence submission.
Show all sections
Sections for TA609
NICE is unable to make a recommendation on tislelizumab (Tevimbra) for treating advanced non-small-cell lung cancer after platinum-based chemotherapy in adults. This is because BeiGene withdrew its evidence submission.
Show all sections
Sections for TA1072
NICE is unable to make a recommendation on vedolizumab (Entyvio) for treating chronic refractory pouchitis after surgery for ulcerative colitis in adults. This is because Takeda did not provide an evidence submission.
Show all sections
Sections for TA826
NICE is unable to make a recommendation on tislelizumab (Tevimbra) for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy in adults. This is because BeiGene withdrew its evidence submission.
Show all sections
Sections for TA1068
NICE is unable to make a recommendation on nivolumab (Opdivo) for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over. This is because Bristol-Myers Squibb did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA980
NICE is unable to make a recommendation about the use in the NHS of lisocabtagene maraleucel (Breyanzi) for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in adults. This is because Celgene did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA987
NICE is unable to make a recommendation on carfilzomib (Kyprolis) with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma in adults. This is because Amgen did not provide an evidence submission.
Show all sections
Sections for TA841
NICE is unable to make a recommendation on vericiguat (Verquvo) for treating chronic heart failure with reduced ejection fraction in adults because Bayer did not provide an evidence submission.
Show all sections
Sections for TA731
Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal) (TA549)
NICE is unable to make a recommendation about the use in the NHS of denosumab for preventing skeletal-related events in multiple myeloma. This is because Amgen did not provide an evidence submission.
Show all sections
Sections for TA549
NICE is unable to make a recommendation on pomalidomide (Imnovid) with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma in adults. This is because Celgene did not provide an evidence submission.
Show all sections
Sections for TA602
NICE is unable to make a recommendation on idecabtagene vicleucel (Abecma) for treating relapsed or refractory multiple myeloma after 2 to 4 treatments in adults. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1084
NICE is unable to make a recommendation on zanubrutinib (Brukinsa) with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma in adults after 2 or more treatments. This is because BeiGene has requested a delay to the evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA978
NICE is unable to make a recommendation on baloxavir marboxil (Xofluza) for treating and preventing influenza in children 1 to 11 years. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1135
NICE is unable to make a recommendation on duvelisib (Copiktra) for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments because Secura Bio withdrew its evidence submission.
Show all sections
Sections for TA811